Avalide, Xopenex Paragraph IV Certifications Filed
This article was originally published in The Pink Sheet Daily
Executive Summary
A Paragraph IV certification for Bristol-Myers Squibb/Sanofi-Aventis' antihypertensive Avalide (irbesartan 300 mg/hydrochlorothiazide 25 mg) tablets was submitted June 6, according to FDA's Aug. 7 updated list of filings